亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Novel Ligands for HIV-1 Protease Inhibitors

總結: Purdue University researchers have designed and synthesized a novel class of HIV-1 protease inhibitors, which show potency 10x greater than that of Darunavir, an FDA-approved inhibitor developed by the same researchers. A number of these inhibitors are very potent against multidrug-resistant HIV-1 variants and could lead to additional drugs used in HIV/AIDS treatment.

技術優勢: HIV therapeutic with 10-fold potency increase over current standardEffective for the treatment of multidrug-resistant strains of HIV

*Background: The AIDS epidemic is one of the most challenging problems in medicine in the 21st century. A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the acquired immune deficiency syndrome (AIDS), a complex disease that includes progressive destruction of the immune system and degeneration of the central and peripheral nervous system. Among many strategies to combat this disease, highly active antiretroviral therapy (HAART) with HIV protease inhibitors (PIs) in combination with reverse transcriptase inhibitors (RTIs) continues to be the first-line treatment for control of HIV infection. This treatment regimen has definitely improved quality of life, enhanced HIV management, and halted the progression of the disease. Today, more people than ever before are living with HIV/AIDS thanks to this first-line treatment. However, despite the impressive success, there remain many challenges to treating this devastating disease, including decreasing both the toxicity and complexity of the treatment regimens. In addition, there is a growing population of patients that are developing multidrug-resistant strains of HIV, and there is ample evidence that these strains can be further transmitted.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，請點擊這裡